Clinical Trial Update: A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 trial update for TAK-831-1001 in healthy participants; the study was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebellar Ataxia
• Schizophrenia

Drugs mentioned

• TAK-831-1001

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia, Cerebellar Ataxia | Phase 1 | Status: TERMINATED | Results posted: 2018-02-06